06682734 is referenced by 35 patents and cites 7 patents.

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

Title
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Application Number
8/475813
Publication Number
6682734 (B1)
Application Date
June 7, 1995
Publication Date
January 27, 2004
Inventor
William H Rastetter
Rancho Sante Fe
CA, US
Mitchell E Reff
San Diego
CA, US
Roland A Newman
San Diego
CA, US
John E Leonard
Encinitas
CA, US
Nabil Hanna
Olivenhain
CA, US
Darrell R Anderson
Escondido
CA, US
Agent
Pillsbury Winthrop
US
Agent
Robin L Teskin
US
Assignee
IDEC Pharmaceuticals Corporation
CA, US
IPC
A61K 39/395
View Original Source